Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.31 -2.32 (-2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
27 28 Next >
News headline image
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' ↗
 
Via Benzinga
News headline image
Incyte Stock Dives On Surprise Rejection For Updated Jakafi ↗
The company had hoped to gain approval for an extended-release version of its biggest drug. 
Via Investor's Business Daily
News headline image
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
From Incyte
Via Business Wire
News headline image
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗
 
Via Benzinga
News headline image
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
From Incyte
Via Business Wire
News headline image
Analyst Expectations for Incyte's Future ↗
 
Via Benzinga
News headline image
Incyte's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
News headline image
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte Corporation
Via Business Wire
News headline image
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
From Incyte Corporation
Via Business Wire
News headline image
Analyst Ratings for Incyte ↗
 
Via Benzinga
News headline image
Earnings Outlook For Incyte ↗
 
Via Benzinga
News headline image
2 Steady Stocks to Buy in a Recession ↗
Both companies are performing better than the broader market over the past year. 
Via The Motley Fool
News headline image
Why Shares of MacroGenics Climbed Thursday ↗
The cancer-focused biotech delivered a strong earnings report. 
Via The Motley Fool
News headline image
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
From Incyte Corporation
Via Business Wire
News headline image
Which S&P 500 Stocks Look Most Attractive Now? ↗
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH. 
Via Talk Markets
News headline image
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns ↗
 
Via Benzinga
News headline image
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
From Incyte Corporation
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
From Incyte
Via Business Wire
News headline image
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone ↗
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily
News headline image
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst ↗
 
Via Benzinga
News headline image
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers ↗
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock... 
Via Talk Markets
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.